Human Health Innovation

Testing New Treatments for NF1

Christof Paparella and Oskar Smrzkafrom Ablevia, Guido Boehmelt, Head of Research Beyond Borders at Boehringer Ingelheim Vienna in the middle

Boehringer Ingelheim Awards Innovation Prize to Ablevia

With a pipeline of around 90 clinical and pre-clinical projects, and the potential to deliver up to 20 new therapy approvals over the next seven years, we continue our track record of long-term innovation-led performance.

Find out more

Science Focus

We are concentrating our research efforts and investment in: CardioMetabolic diseases; Central Nervous System diseases; Immunology and Respiratory diseases; Oncology and Cancer Immunology and Retinal health.

View this Section

Fostering Science

Creating breakthrough medicines that change patients’ lives starts with a commitment to identify the health challenges of the future and advance emerging science.

View this Section

Grass Roots

We’re supporting early-stage companies to progress their science through our global program of initiatives that provides mentoring, education & valuable resources, the opportunity to network & share experiences with fellow innovators and entrepreneurs.

View this Section

Science Stories

Every day our scientists are inspired to start new journeys of discovery that could lead to the next breakthrough. Find out more about those journeys through their science stories.

View this Section

Clinical Studies

Clinical trials are an essential part of the development of new medicines. They are the translation of our scientific expertise into breakthrough therapies for patients.

View this Section